There is a great unmet need for discovering biomarkers that can be used to diagnose early or covert disease, predict responsiveness to therapy or monitor the efficacy of treatment regimens. Reccan Diagnostics has a strong scientific expertise in identifying protein targets specific for clinical application through discovery by using mass spectrometry. Proteomic studies includes various technical disciplines, where Reccan Diagnostics has cutting edge capability and experience. In particular, Reccan Diagnostics have adopted the use of Multiple Reaction Monitoring Mass Spectrometry (MRM-MS) on which a high throughput platform has been built for rapid screening of samples in a simultaneously cost efficient, quantitative, and extremely accurate way. Today, we rely on many forms of comparative clinical metadata, which we align and use together with mass spectrometry protein sequence data, hunting for clinical correlations by computational science. These include (but are not limited to) laboratory measurements used to monitor health status, medical imaging records describing disease structural features and functional measurements used to diagnose disease stages.


Clinical studies and sample repository

Disease treatments will in the future be entirely dependent on precision diagnostics to find responders. Reccan Diagnostics has access to high quality clinical biobank material (blood and tissue) combined with extensive register data for patients and a cutting edge mass spectrometric technology, which provides optimal possibilities to develop diagnostic assays.
This provides the opportunity to develop a variety of products for various indications:

  • screening
  • diagnosis
  • staging and prognosis
  • probe for diagnostic imaging
  • prediction of treatment response (companion diagnostics)



The primary focus of Reccan Diagnostics AB is to develop a protein-based in vitro diagnostic assay for diagnosis of pancreatic cancer in patient serum samples as well as a diagnostic tool for prognosis of pancreatic cancer in tissue. Once proof of concept in pancreatic cancer is established, the development strategy used for pancreatic cancer will be applied to other solid cancers, such as biliary, liver and colorectal cancer.